Literature DB >> 27866850

Deubiquitination and Stabilization of PD-L1 by CSN5.

Seung-Oe Lim1, Chia-Wei Li1, Weiya Xia1, Jong-Ho Cha2, Li-Chuan Chan3, Yun Wu4, Shih-Shin Chang3, Wan-Chi Lin1, Jung-Mao Hsu1, Yi-Hsin Hsu1, Taewan Kim1, Wei-Chao Chang5, Jennifer L Hsu6, Hirohito Yamaguchi1, Qingqing Ding1, Yan Wang1, Yi Yang1, Chung-Hsuan Chen7, Aysegul A Sahin4, Dihua Yu3, Gabriel N Hortobagyi8, Mien-Chie Hung9.   

Abstract

Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified tumor necrosis factor alpha (TNF-α) as a major factor triggering cancer cell immunosuppression against T cell surveillance via stabilization of programmed cell death-ligand 1 (PD-L1). We demonstrated that COP9 signalosome 5 (CSN5), induced by NF-κB p65, is required for TNF-α-mediated PD-L1 stabilization in cancer cells. CSN5 inhibits the ubiquitination and degradation of PD-L1. Inhibition of CSN5 by curcumin diminished cancer cell PD-L1 expression and sensitized cancer cells to anti-CTLA4 therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CSN5; PD-L1; TNF-α; anti-CTLA4; curcumin; deubiquitination

Mesh:

Substances:

Year:  2016        PMID: 27866850      PMCID: PMC5171205          DOI: 10.1016/j.ccell.2016.10.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  40 in total

Review 1.  NF-κB signaling pathways regulated by CARMA family of scaffold proteins.

Authors:  Marzenna Blonska; Xin Lin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

2.  Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation.

Authors:  Mei Wan; Xuesong Cao; Yalei Wu; Shuting Bai; Liyu Wu; Xingming Shi; Ning Wang; Xu Cao
Journal:  EMBO Rep       Date:  2002-01-29       Impact factor: 8.807

3.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

4.  COP9 signalosome controls the Carma1-Bcl10-Malt1 complex upon T-cell stimulation.

Authors:  Verena Welteke; Andrea Eitelhuber; Michael Düwel; Katrin Schweitzer; Michael Naumann; Daniel Krappmann
Journal:  EMBO Rep       Date:  2009-05-15       Impact factor: 8.807

5.  Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.

Authors:  Jin Peng; Junzo Hamanishi; Noriomi Matsumura; Kaoru Abiko; Kumuruz Murat; Tsukasa Baba; Ken Yamaguchi; Naoki Horikawa; Yuko Hosoe; Susan K Murphy; Ikuo Konishi; Masaki Mandai
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 7.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

8.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

9.  NF-κB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment.

Authors:  Gang Huang; Qianjun Wen; Yongliang Zhao; Qiangguo Gao; Yun Bai
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  220 in total

1.  Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.

Authors:  Ailing Wu; Qingzhe Wu; Yujie Deng; Yuning Liu; Jinqiu Lu; Liansheng Liu; Xiaoling Li; Cheng Liao; Bin Zhao; Hai Song
Journal:  EMBO J       Date:  2018-11-05       Impact factor: 11.598

Review 2.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

Review 3.  Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer.

Authors:  Constantinos P Zambirinis; George Miller
Journal:  Trends Mol Med       Date:  2017-04-08       Impact factor: 11.951

Review 4.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

5.  CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.

Authors:  Hongliang Liu; Junwen Hu; Hua Pan; Dilai Luo; Mingwen Huang; Wei Xu
Journal:  Dig Dis Sci       Date:  2017-11-30       Impact factor: 3.199

6.  Excess of the NF-ĸB p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1- and chemokines-mediated mechanisms.

Authors:  Yelena Kravtsova-Ivantsiv; Gilad Goldhirsh; Alexandra Ivantsiv; Ofer Ben Itzhak; Yong Tae Kwon; Eli Pikarsky; Aaron Ciechanover
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-09       Impact factor: 11.205

7.  The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.

Authors:  Yuan Wei; Qiyi Zhao; Zhiliang Gao; Xiang-Ming Lao; Wei-Ming Lin; Dong-Ping Chen; Ming Mu; Chun-Xiang Huang; Zheng-Yu Liu; Bo Li; Limin Zheng; Dong-Ming Kuang
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

8.  PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

Authors:  Marién Pascual; María Mena-Varas; Eloy Francisco Robles; Maria-Jose Garcia-Barchino; Carlos Panizo; Sandra Hervas-Stubbs; Diego Alignani; Ainara Sagardoy; Jose Ignacio Martinez-Ferrandis; Karen L Bunting; Stephen Meier; Xavier Sagaert; Davide Bagnara; Elizabeth Guruceaga; Oscar Blanco; Jon Celay; Alvaro Martínez-Baztan; Noelia Casares; Juan José Lasarte; Thomas MacCarthy; Ari Melnick; Jose Angel Martinez-Climent; Sergio Roa
Journal:  Blood       Date:  2019-04-11       Impact factor: 22.113

9.  Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.

Authors:  Ying Wang; Xin Zhang; Xin Xie; Wei Chen; Min Li; Dongmei Diao; Chengxue Dang
Journal:  Cancer Biol Ther       Date:  2020-11-20       Impact factor: 4.742

Review 10.  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Authors:  Jinfang Zhang; Fabin Dang; Junming Ren; Wenyi Wei
Journal:  Trends Biochem Sci       Date:  2018-10-01       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.